Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib as Neoadjuvant Therapy in Advanced Colorectal Cancer
NCT03377842Phase 2Unknown
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jan 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in colorectal cancer (CRC) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoints: R0, R1 or R2 resection and Progression-free survival at 8 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03377842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377842.